December 2006 in “Lancet Oncology” In men aged 40–60 years with androgenic alopecia, this study found that 1 mg/day finasteride reduced serum PSA concentrations by 40-50% after 48 weeks compared to placebo.
February 2007 in “Lancet Oncology” This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.
67 citations
,
December 2015 in “Journal of the National Comprehensive Cancer Network” This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.
January 2009 in “The Hastings Center Report” This review discusses the preventive use of finasteride for prostate cancer and highlights the unresolved safety concerns and potential over-diagnosis associated with its widespread recommendation.
January 2023 in “International Journal of Clinical and Medical Education Research” This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.
